Early data from an Australian registry of HIFU-treated patients

We should preface the following commentary by stating that there is no doubt that it takes time to learn to use high-intensity focused ultrasound (HIFU) really well as a form of first-line treatment for localized prostate cancer. This is hardly surprising.

Combinations of HIFU + radiation as salvage therapy for recurrent prostate cancer

A newly published paper from a clinical research group in Nice, France, has reported very limited data on a small cohort of patients with recurrent localized prostate cancer after first-line therapy who were given salvage therapy using various combinations of radiation therapy and high-intensity focused ultrasound (HIFU).

Where your $25,000 goes when you get HIFU in Mexico

An article in the Sunday edition of the San Francisco Chronicle has raised questions about how physicians are reimbursed for carrying out high-intensity focused ultrasound (HIFU) procedures on prostate cancer patients in the Caribbean and Mexico.

Advisory committee votes against approval of SonoCare HIFU

According to a report posted yesterday on the Medscape web site, a Food and Drug Administration (FDA) advisory committee “voted October 1 not to recommend approval, at least for now” of a SonoCare Medical’s Sonablate high-intensity focused ultrasound (HIFU) device to treat patients with radio-recurrent

Three generations of Sonablate HIFU equipment … the data from Japan

Over the weekend, one of our regular commentators brought to our attention a newly published, retrospective analysis of data on the risks and benefits of treatment of localized prostate cancer with three successive generations of high-intensity focused ultrasound (HIFU) equipment from the company now known as Sonocare Medical.

FDA has questions about Ablatherm HIFU device

According to a report on the Bloomberg News web site, the FDA’s reviewers appear to be less than enthusiastic about the effectiveness and safety data submitted by EDAP TMS to support approval of the Ablatherm device for use of high-intensity focused ultrasound (HIFU) for the treatment of low-risk forms of prostate cancer.

FDA schedules meetings to review PMAs for Ablatherm’s, SonoCare’s HIFU devices

According to a media release issued earlier today by EDAP TMS, the U.S. Food and Drug Administration (FDA) has scheduled a meeting on July 30, 2014, to review the Pre-Market Approval (PMA) application for EDAP’s Ablatherm-HIFU device for the treatment of localized prostate cancer.

Outcomes after first-line and repeat HIFU procedures in the UK

In the UK, the team led by Drs Ahmed and Emberton has been meticulous in its collection and reporting of outcome data related to their investigational use of high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer.

Morbidity associated with HIFU at three UK academic centers

A group of three centers in the UK has been investigating the appropriate use of high-intensity focused ultrasound (HIFU) since 2004.

8-year bPFS data for 1,000+ French HIFU patients

A French clinical research group has just reported 8-year biochemical progression-free survival (bPFS) data for > 1,000 men with localized prostate cancer treated with first-line high-intensity focused ultrasound (HIFU). We assume that these data were generated using the Ablatherm HIFU technology.

Ablatherm HIFU data on 5,000+ patients with T1 to T3 localized prostate cancer

Another paper to be presented at the upcoming annual meeting of the American Urological Association (AUA) offers us some additional data on the effectiveness and safety of high-intensity focused ultrasound (HIFU) carried out using the Ablatherm technology and recorded in the @-Registry database.

Ablatherm HIFU data on low-risk patients from the @-Registry

A new study to be presented at the upcoming annual meeting of the American Urological Association in San Diego will provide data on the first-line treatment of some 358 men with low-risk prostate cancer collected in the @-Registry, all of whom received treatment with high-intensity focused ultrasound (HIFU) using the Ablatherm® form of this technology.

Finally … Some real 5-year outcome data on HIFU, but were the right patients being treated?

“Medium term outcomes” data following first-line treatment with high-intensity ultrasound (HIFU) are to be presented at the upcoming annual meeting of the American Urological Association.

US FDA accepts data filing for Ablatherm HIFU technology

According to a media release issued by EDAP TMS SA yesterday, the U.S. Food & Drug Administration (FDA) has issued a positive Filing Review Notification to the company with respect to EDAP TMS’s Pre-Market Approval (PMA) application for its Ablatherm Integrated Imaging HIFU (High Intensity Focused Ultrasound) device.

HIFU outcomes in Germany after an average of 8 years of follow-up

Researchers at the University of Regensburg in Germany have just reported progression-free survival data from their 14-year experience of using high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. This research group was one of the first to start testing the use of HIFU in the treatment of prostate cancer.


Get every new post delivered to your Inbox.

Join 1,300 other followers